Skip to NavigationSkip to content

Celgene signs $1.5bn partnership with Immatics to fight cancer with engineered T-cell therapies

Published on 29/08/19 at 11:32am

Celgene and biopharma firm Immatics Biotechnologies have announced that they have entered a partnership valued at a potential $1.5 billion to pursue the development of T-cell receptor-engineered T-cell therapies (TCR-T) for a range of cancer types.

The pair will leverage Immatics’ XPRESIDENT technology and XCEPTOR TCR discovery and engineering platform to develop immunotherapies based on the method of engineering T-cells of patients to express a specific receptor.

As part of the deal, Immatics will receive an upfront payment of $75 million for three programmes, and is eligible to receive an additional $505 million for each programme that achieves prespecified developmental and commercial milestones. Celgene will have the option to assume worldwide commercial and manufacturing responsibility for any of these therapies, though Immatics maintains early stage co-development rights or co-funding rights for selected products developed as part of the collaboration.

“We are delighted to enter into this strategic collaboration with Celgene. This alliance leverages Immatics’ excellence in developing adoptive cell therapies (ACT) and complements our proprietary clinical pipeline of ACT products and our strong portfolio of Bispecific products”, explained Harpreet Singh, CEO of Immatics. “By combining Immatics’ world-leading discovery engines as well as our cellular manufacturing and clinical development platforms with Celgene’s broad expertise in cell therapy research, development and commercialisation, the companies join forces to enable the development of truly novel opportunities for patients with solid tumours who currently have no other treatment options.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches